Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Aficamten→

Aficamten Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2364554-48-1
Molecular formula
C18H19N5O2
Molecular weight
337.4 g/mol
Drug class
Cardiac myosin inhibitorallosteric, reversible sarcomere modulator
Mechanism of action
Allosterically and reversibly inhibits cardiac myosin motor activity, reducing force generation at the cardiac sarcomere. This decreases myocardial contractility and left-ventricular outflow-tract obstruction in hypertrophic cardiomyopathy.
Indications / reported uses
  • Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms under the US FDA indication; requires product-specific echocardiographic monitoring and risk controls

Sources: US FDA — Drug Trials Snapshot: MYQORZO (approval 19 Dec 2025) · NLM DailyMed — MYQORZO prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Aficamten Environmental Risk Assessment (ERA) (the Aficamten ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.